Table A2.
Cardiac Marker Data
| Cardiac Marker (cutoff for abnormal) | Baseline Data |
Treatment Regimen |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AC |
T |
T + H |
H |
||||||||||||
| No. of Patients | Median (min, max) | No. Abnormal | No. of Patients | Median (min, max) | No. Abnormal | No. of Patients | Median (min, max) | No. Abnormal | No. of Patients | Median (min, max) | No. Abnormal | No. of Patients | Median (min, max) | No. Abnormal | |
| BNP (> 40 ng/mL) | 65 | 13.7 (< 4.0, 156) | 7 | 68 | 15.6 (< 4.0, 179) | 8 | 5 | 17.2 (12.3, 49.9) | 1 | 73 | 14.1 (< 4.0, 191) | 9 | 61 | 4.7 (< 4.0, 120) | 3 |
| CRP (> 0.3 mg/L) | 69 | 2 (0.2, 25.6) | 26 | 68 | 2.4 (0.3, 40.7) | 31 | 5 | 3.3 (1.9, 4.4) | 3 | 73 | 2 (0.1, 32.8) | 29 | 63 | 2.1 (< 0.1, 40.1) | 27 |
| TnT (> 0.01 μg/mL) | 68 | < 0.01 (< 0.01, 0.01) | 0 | 68 | < 0.01 (< 0.01, 0.01) | 0 | 5 | < 0.01 (< 0.01, 0.01) | 0 | 73 | < 0.01 (< 0.01, 0.06) | 7 | 63 | < 0.01 (< 0.01, 0.02) | 2 |
| TNF-α (> 4.71 pg/mL) | 69 | 1.6 (< 0.05, 14) | 3 | 68 | 1.2 (< 0.5, 3.4) | 0 | 5 | 1.4 (0.56, 2.2) | 0 | 72 | 1.4 (< 0.5, 25) | 2 | 62 | 1.5 (< 0.5, 35) | 8 |
| IL-1β (> 0.54 pg/mL) | 67 | < 0.5 (< 0.5, 1.9) | 5 | 68 | < 0.5 (< 0.5, 3.7) | 1 | 5 | < 0.5 (< 0.05, < 0.05) | 0 | 73 | < 0.5 (< 0.5, 0.9) | 1 | 61 | < 0.5 (< 0.5, 1.9) | 2 |
| TnI (> 0.04 mcg/mL) | 68 | 0.01 (< 0.01, 0.07) | 6 | 68 | 0.01 (< 0.01, 24.1) | 6 | 5 | 0.04 (0.01, 0.08) | 1 | 73 | 0.03 (< 0.01, 8.16) | 17 | 61 | 0.02 (< 0.01, 10) | 3 |
| IL-6 (> 10 pg/mL) | 68 | 2 (0.8, 22.4) | 4 | 69 | 1.9 (0.6, 27.5) | 1 | 5 | 1.3 (0.4, 3.7) | 0 | 73 | 1.8 (< 0.3, 27.6) | 3 | 60 | 3.55 (0.4, 128) | 5 |
Abbreviations: AC, doxorubicin plus cyclophosphamide; BNP, brain natriuretic peptide; CRP, C-reactive protein; IL, interleukin; T, paclitaxel; T + H, paclitaxel plus trastuzumab; Tn, troponin; TNF, tumor necrosis factor.